SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
1-Year Return
0.41%
This Quarter Return
-3.6%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$614M
AUM Growth
-$3.99M
(-0.65%)
Cap. Flow
+$47.9M
Cap. Flow
% of AUM
7.81%
Top 10 Holdings %
Top 10 Hldgs %
28.66%
Holding
127
New
28
Increased
30
Reduced
32
Closed
11
Top Buys
| 1 |
Skye Bioscience
SKYE
|
$10.4M |
| 2 |
ASML
ASML
|
$10.1M |
| 3 |
Apple
AAPL
|
$9.27M |
| 4 |
Amazon
AMZN
|
$9.08M |
| 5 |
Salesforce
CRM
|
$8.64M |
Top Sells
| 1 |
Teva Pharmaceuticals
TEVA
|
$17.9M |
| 2 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
$9.57M |
| 3 |
Camtek
CAMT
|
$9.14M |
| 4 |
Nova
NVMI
|
$6.23M |
| 5 |
SentinelOne
S
|
$5.62M |
Sector Composition
| 1 | Healthcare | 71.02% |
| 2 | Technology | 20.47% |
| 3 | Communication Services | 3.65% |
| 4 | Consumer Discretionary | 3.59% |
| 5 | Utilities | 0.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Global E Online
GLBE
$5.94B
| $2.43M | 0.33% |
66,884
-141,900
| -68% | -$5.15M |
|
77
Ventyx Biosciences
VTYX
$185M
| $2.34M | 0.32% |
1,012,749
+20,000
| +2% | +$46.2K |
|
78
Taboola.com
TBLA
$994M
| $2.3M | 0.31% |
667,384
-523,686
| -44% | -$1.8M |
|
79
Larimar Therapeutics
LRMR
$332M
| $2.27M | 0.31% |
+312,469
| New | +$2.27M |
|
80
L3Harris
LHX
$51.1B
| $2.25M | 0.31% |
+10,000
| New | +$2.25M |
|
81
ADC Therapeutics
ADCT
$380M
| $2.17M | 0.3% |
+685,547
| New | +$2.17M |
|
82
Nutrien
NTR
$27.7B
| $2.07M | 0.28% |
40,730
+5,000
| +14% | +$255K |
|
83
Perion Network
PERI
$411M
| $1.96M | 0.27% |
+234,609
| New | +$1.96M |
|
84
Kyverna Therapeutics
KYTX
$156M
| $1.77M | 0.24% |
+236,029
| New | +$1.77M |
|
|
ALMS
85
Alumis Inc. Common Stock
ALMS
$474M
| $1.66M | 0.23% |
+125,000
| New | +$1.66M |
|
|
CLYM
86
Climb Bio, Inc. Common Stock
CLYM
$158M
| $1.53M | 0.21% |
+215,179
| New | +$1.53M |
|
87
Werewolf Therapeutics
HOWL
$61.7M
| $1.53M | 0.21% |
626,810
| – | – |
|
88
Astria Therapeutics
ATXS
$396M
| $1.48M | 0.2% |
162,842
+50,000
| +44% | +$455K |
|
89
Vir Biotechnology
VIR
$717M
| $1.44M | 0.2% |
+162,051
| New | +$1.44M |
|
90
Monte Rosa Therapeutics
GLUE
$303M
| $1.4M | 0.19% |
+375,000
| New | +$1.4M |
|
91
Marvell Technology
MRVL
$55.3B
| $1.4M | 0.19% |
+20,000
| New | +$1.4M |
|
92
Upwork
UPWK
$2.23B
| $1.26M | 0.17% |
117,000
| – | – |
|
93
Arrowhead Research
ARWR
$3.88B
| $1.25M | 0.17% |
+48,175
| New | +$1.25M |
|
94
Compugen
CGEN
$133M
| $1.24M | 0.17% |
739,239
-30,000
| -4% | -$50.4K |
|
95
Kezar Life Sciences
KZR
$27.9M
| $1.23M | 0.17% |
205,168
| – | – |
|
96
Insmed
INSM
$30.1B
| $1.11M | 0.15% |
+16,589
| New | +$1.11M |
|
97
Aprea Therapeutics
APRE
$8.74M
| $1.1M | 0.15% |
270,000
| – | – |
|
98
TSMC
TSM
$1.22T
| $982K | 0.13% |
+5,650
| New | +$982K |
|
|
ELEV
99
DELISTED
Elevation Oncology
ELEV
| $891K | 0.12% |
330,000
-100,000
| -23% | -$270K |
|
100
Varonis Systems
VRNS
$6.24B
| $768K | 0.1% |
16,000
-4,000
| -20% | -$192K |
|